Quick answer
When the tumor is confined to the prostate, the cancer can be cured with surgery or radiotherapy.4 In the British ProtecT trial, 2.7% of men with localized cancer died of the disease within 15 years, with similar numbers after surgery and after radiotherapy.5 After treatment, the PSA shows whether the cancer has been controlled, and it should become undetectable after prostatectomy.8 Each person's outlook depends on the risk group, the ISUP grade group and the stage.3
What the numbers show
Apart from non-melanoma skin cancer, prostate cancer is the most common cancer in men in Brazil, with 77,920 new cases estimated per year from 2026 to 2028.1
The SEER program of the US National Cancer Institute measures relative survival, which compares men with the cancer with men of the same age without it. With data from 2016 to 2022:2
| Stage at diagnosis | Share of cases | Five-year relative survival |
|---|---|---|
| Confined to the prostate | 69% | Close to 100% |
| In the area around the prostate or nearby lymph nodes | 14% | Close to 100% |
| With distant metastases | 9% | 40.1% |
Five years is a short time to talk about cure. That is why the studies with 15 years or more of follow-up, further down, say more about it.
When the cancer has already spread far from the prostate, treatment aims to control the disease. Hormone therapy can slow progression and prolong life.12
What being cured means
We talk about cure when the cancer has been treated and does not come back. In prostate cancer, the PSA tells that story over the years.
- After prostatectomy: the whole prostate is removed, and the PSA should become undetectable in about two months.8 In my practice, the first PSA is checked at about 1 month. The page on PSA after prostatectomy explains each result.
- After radiotherapy: the prostate stays in the body, and the PSA falls slowly. Recurrence is defined as a rise of 2 ng/mL above the lowest value the PSA reached.8 More on PSA rising after radiotherapy.
- Follow-up: PSA is checked every six months for three years and then once a year.8
What studies show about surgery and radiotherapy
Three studies help answer the question with long-term numbers:
- ProtecT (United Kingdom): 1,643 men with localized cancer found through PSA testing were randomized to active monitoring, surgery or radiotherapy. At 15 years, 2.7% had died of the disease: 3.1% with monitoring, 2.2% with surgery and 2.9% with radiotherapy, with no statistical difference. Metastases appeared in 9.4% with monitoring, 4.7% with surgery and 5.0% with radiotherapy.5
- SPCG-4 (Scandinavia): 695 men with localized cancer, detected clinically without PSA screening, were randomized to radical prostatectomy or watchful waiting. At 29 years, surgery reduced deaths from the cancer by 11.7 percentage points. On average, the men who had surgery gained 2.9 years of life at 23 years.6
- Surgical series of 12,677 men: operated on between 1987 and 2005 at several centers. At 15 years, 12% had died of the cancer. Only 4% of the more recent patients had a predicted risk above 5%.7
ProtecT shows that, in localized cancer, surgery and radiotherapy controlled the disease in a similar way.5 The page on surgery or radiotherapy compares the side effects of each. When surgery is the choice, I perform robotic radical prostatectomy.
What changes the outlook
The European guideline groups localized cancer by risk using the biopsy ISUP grade group, the PSA and the rectal exam:3
| Group | How it is defined |
|---|---|
| Low risk | ISUP 1, PSA below 10 ng/mL and tumor confined to the prostate on the rectal exam |
| Intermediate risk | ISUP 2 or 3, or PSA between 10 and 20 ng/mL, with tumor confined to the prostate on the rectal exam |
| High risk | ISUP 4 or 5, or PSA above 20 ng/mL |
| Locally advanced | Tumor beyond the prostate on the rectal exam (cT3 or cT4) or suspicious lymph nodes on imaging |
The numbers confirm the weight of these factors. In SPCG-4, among the men who had surgery, the risk of dying of the cancer was 5 times higher when the tumor had grown through the capsule and 10 times higher with a Gleason score above 7.6 In the series of 12,677 men, the biopsy Gleason grade and the PSA were linked to the risk of death from the cancer.7
The page on Gleason and ISUP explains the biopsy grade.
What if the PSA rises again
When the PSA rises again after treatment, we call it biochemical recurrence. It shows that some cancer cells remained, but what happens next varies a lot.
In a group of 1,997 men who had surgery, recurrence was defined as a PSA of 0.2 ng/mL or more. It occurred in 15% of them. Among these, 34% developed metastases during the study, at a median of 8 years after the PSA rise.9 A review of 77 studies showed that recurrence affects survival mainly when the PSA doubles quickly and when the Gleason score on the pathology report is high.10
So a rising PSA calls for a calm conversation about tests and salvage treatment. Salvage radiotherapy is one of the options after surgery, as the page on PSA after prostatectomy explains.
What to do after the diagnosis
A diagnosis is frightening. The first step is to understand your case calmly, with the right tests:
- Know your risk group. The biopsy gives the ISUP grade group, and the PSA, the rectal exam and the MRI complete the classification.3
- Check whether the cancer has left the prostate. In high-risk disease, PSMA PET had an accuracy of 92%, against 65% for CT with a bone scan, in the proPSMA trial.11
- Learn the options. In low-risk disease, active surveillance follows the tumor closely and avoids treating men who do not need it. In intermediate-risk and high-risk disease, surgery and radiotherapy come in.4
- Ask for another assessment if you wish. A second opinion can be done entirely online, in English, with your test results sent in advance.
- Do not let too much time pass. Treatment can wait up to three months without harming cancer control, according to the European guideline.4 When I recommend surgery for intermediate-risk or high-risk disease, I advise operating as soon as possible. Hormone therapy before prostatectomy is not indicated,4 and I do not use hormone therapy while the patient waits for surgery.
How I work
At the consultation, I review the biopsy, PSA, MRI and other tests and explain which risk group your case falls into. We talk about what the numbers mean for someone with your profile, without promises and without rushing the explanations.
I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I have performed robotic radical prostatectomy since 2020, and I preserve the erection nerves whenever possible.
After treatment, I follow your PSA with you. If you live far away, follow-up visits can be done online.
Send your case
If you have received a diagnosis and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
Is prostate cancer curable?+
When the tumor is confined to the prostate, it can be cured with surgery or radiotherapy.4 In the British ProtecT trial, with 1,643 men with localized cancer, 2.7% died of the disease within 15 years.5 Each person's outlook depends on the risk group, the ISUP grade group and the stage.3
What are the chances of surviving prostate cancer?+
In the United States, with data from 2016 to 2022, five-year relative survival was close to 100% when the cancer was confined to the prostate or had only reached the area around it, and 40.1% when there were distant metastases.2 These numbers come from large groups and do not predict what will happen to one person.
Can surgery cure prostate cancer?+
It can when the tumor is confined to the prostate.4 In the Scandinavian SPCG-4 trial, followed for 29 years, radical prostatectomy reduced deaths from the cancer by 11.7 percentage points compared with watchful waiting.6 In a series of 12,677 men who had surgery, 12% died of the cancer within 15 years, and only 4% of the more recent patients had a predicted risk above 5%.7
Surgery or radiotherapy, which cures more?+
In ProtecT, death from the cancer at 15 years was 2.2% after surgery and 2.9% after radiotherapy, with no statistical difference.5 The two differ in their effects on urine, erections and the bowel, and the choice depends on the tumor, your health and what you want to preserve.4
How do I know if I am cured after treatment?+
Through the PSA. After prostatectomy, the PSA is expected to be undetectable about two months later. After radiotherapy, the PSA falls slowly, and recurrence is defined as a rise of 2 ng/mL above the lowest value reached. PSA is checked every six months for three years and then once a year.8
If my PSA rises again, has the cancer come back?+
A rising PSA, called biochemical recurrence, shows that some cancer cells remained, but it does not always lead to metastases. In a group of 1,997 men who had surgery, 15% had their PSA rise back to 0.2 ng/mL or more, and 34% of those developed metastases during the study.9 The risk is higher when the PSA doubles quickly and when the Gleason score on the pathology report is high.10
How long can I wait before treatment?+
According to the European guideline, treatment can be delayed for up to three months after diagnosis without harming cancer control.4 In my practice, when I recommend surgery for intermediate-risk or high-risk disease, I advise operating as soon as possible, without hormone therapy while waiting.
Who operates on prostate cancer in São Paulo?+
I do. I am a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I have performed robotic radical prostatectomy since 2020. The first consultation can be online, in English, and a second opinion can be done entirely online.
References
- Instituto Nacional de Câncer. Estimativa 2026-2028: incidência de câncer no Brasil. Síntese de resultados e comentários. Rio de Janeiro: INCA; 2026. INCA
- National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. Data from 2016 to 2022. NCI
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMed
- Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018;379(24):2319-2329. PubMed
- Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27(26):4300-4305. PubMed
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: follow-up. European Association of Urology; 2026. EAU
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597. PubMed
- Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967-987. PubMed
- Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. PubMed
- National Cancer Institute. Hormone Therapy for Prostate Cancer. 2024. NCI
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
